Dulaglutide medication contains the active component dulaglutide. It is an antidiabetic medication used for the treatment of type 2 diabetes. Belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), Dulaglutide injection works by mimicking the natural GLP-1 hormone that regulates insulin secretion and blood glucose control.

It is often prescribed when diet and exercise alone are insufficient and may be used along with other diabetes treatments such as metformin or sulfonylureas. This drug helps improve glycemic control, reduce the risk of hyperglycemia and hypoglycemia, and may support moderate weight loss, one of the notable dulaglutide benefits.

In India, dulaglutide injection India is available under various dulaglutide brand name India options, the most well-known being Trulicity, widely prescribed for dulaglutide for diabetes India. The FDA approved this medication on September 17, 2014, for the treatment of type 2 diabetes.

Dulaglutide is a medication approved for the management of type 2 diabetes.

Dulaglutide is typically administered by a healthcare professional once in a week. It is usually given as an injection. The healthcare provider will determine the dosage and duration of treatment based on the specific infection and individual factors.

Dulaglutide, like any medication, can have side effects. Common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. These side effects are usually mild to moderate in intensity and tend to improve over time. Less common but more serious side effects can include pancreatitis, characterized by severe abdominal pain, and allergic reactions such as anaphylaxis. Other potential side effects include thyroid C-cell tumors, injection site reactions, and an increased heart rate.

Dulaglutide warnings include the potential risk of thyroid C-cell tumors, especially in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome types 2. Pancreatitis, a rare but serious condition, has been reported in patients taking this medication. Using this medicine in combination with insulin can increase the risk of hypoglycemia. Cardiovascular safety, potential injection site reactions, and the lack of established safety in pediatric use are also important considerations. 

It is crucial to consult with a healthcare professional and carefully review the warnings associated with dulaglutide to ensure safe and appropriate use. Precautions include monitoring renal function in patients with moderate to severe renal impairment and using this medication with caution in these individuals. Close monitoring of glycemic control is essential when combining it with insulin to minimize the risk of hypoglycemia. Patients with a history of cardiac arrhythmias or unstable cardiovascular disease may require careful monitoring due to the potential increase in heart rate associated with this medication.

Before receiving the Dulaglutide, inform your healthcare provider about any known allergies, previous adverse reactions. Be aware of adverse side effects and seek immediate medical attention if any of them occur. Take precautions when using it, such as monitoring renal function if you have moderate to severe renal impairment and when combining this medication with insulin secretagogues or insulin to prevent hypoglycemia. If you have a history of cardiac arrhythmias or unstable cardiovascular disease, close monitoring may be necessary due to its possible increased heart rate. Follow proper injection technique and site rotation to minimize the risk of injection site reactions. If you are pregnant or breastfeeding, carefully weigh this medication potential risks and benefits with your healthcare professional.

1. Eli Lilly and Company Limited, Electronic medicines compendium (EMC), [Revised on 25th May 2023], [Accessed on 31st May 2023], https://www.medicines.org.uk/emc/files/pil.3634.pdf
2. Eli Lilly and Company, US Food and Drug Administration, [Revised on January 2017] [Accessed on 1st June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf 
3. KD Tripathi, Essentials of Medical Pharmacology, 2018, 8th Edition, 1002-1008

The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.